Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

works as designed to address the underlying immune suppression observed in metastatic RCC patients, while also generating a highly specific and durable T-cell response that appears to improve clinical outcomes in terms of PFS, when combined with sunitinib," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "This is the first prospective analysis of immunodynamics in RCC patients receiving sunitinib in combination with an immunotherapy, and we plan to confirm these positive results in a randomized setting in a Phase 3 clinical trial."

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:

David Schull or Andreas
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Orexigen® Therapeutics, Inc. (Nasdaq: OREX ) today ... UBS Global Healthcare Conference in New York ... at 11 a.m. Eastern Time. To listen to the ... the Investor Relations section of the Company,s Web site at ... days after the event. About Orexigen® Therapeutics ...
(Date:5/17/2013)... DIEGO and CAMBRIDGE, Mass., May 17, 2013 /PRNewswire/ ... that a purchaser of Aveo Pharmaceutical, Inc. (NASDAQGS: AVEO) ... Court for the District of Massachusetts ... its officers violated the Securities Exchange Act of 1934 ... 1, 2013 (the "Class Period"). (Logo: ...
(Date:5/17/2013)... Ill. , May 17, 2013  Sony Biotechnology ... Sony SP6800 Spectral Analyzer (SP6800).  Sony will be exhibiting ... which will be held at the San ... Diego, California , from May 20 - 22.  ... second analytical system, incorporating commercial audio-visual technologies into new ...
Breaking Medicine Technology:Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2
... PLYMOUTH MEETING, Pa., June 9 Genaera,Corporation ... presentation by Genaera,scientists of preclinical data on ... treatment of type 2 diabetes and obesity, ... Diabetes Association in San,Francisco, California., The ...
... SUNNYVALE, Calif., June 9 Pharmacyclics, Inc.,(Nasdaq: ... study evaluating,PCI-32765, an orally available, selective inhibitor of ... an established animal model,for rheumatoid arthritis (RA). The ... Societies (FOCIS) meeting being held this,week in Boston, ...
Cached Medicine Technology:Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 2Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 3Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association 4Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 2Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 3Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma 4
(Date:5/18/2013)... Utah (PRWEB) May 18, 2013 ... on insurance agents’ role in Marketplaces . ... to traditional employer sponsored health benefits, is the ... and health reimbursement arrangements . , ... Health and Human Services (HHS) recently released a ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... Although obesity is associated with an increased ... and esophageal adenocarcinoma, a type of esophageal cancer, is ... reported on Cancer.gov, last reviewed in January 2012, ... as those of normal and healthy weight to develop ... esophageal cancer is not well understood, it is now ...
(Date:5/18/2013)... May 18, 2013 Show And Go Training, ... various different training systems that is all about is getting ... the attention of http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting ... is a unique “four phase system” designed to make you ... of time spent working out in the gym. The training ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 2Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 3Health News:Zane Benefits Publishes New Information on Insurance Agents’ Role in Marketplaces 4Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2
... Drugs,(NYSE: LDG ) announced its flu immunization program at ... of those communities remain,healthy and combat the annual flu season. ... meet its customers, needs. -- Longs Drugs will be ... beginning in October through the middle of November. ...
... for Trading on OTC Bulletin Board Shortly -, ... Board: EMED) announced today that the U.S. Securities and,Exchange ... by Card Activation Technologies, Inc. As a result of,the ... its Form 211 application, as filed with the NASD, ...
... 24 With the cold and,flu season now upon ... to washing their hands on a regular basis because,according ... hands is,the single most important measure people can take ... "Studies have shown that 40 percent of women and ...
... Cancer Center at Jefferson and Thomas Jefferson University Hospital ... implant radiation-emitting seeds in prostate cancer patients. While the ... based in The Netherlands, is only being used for ... help with the actual placement of the seeds. To ...
... Hope",charity auction, hosted by Pittsburgh Steeler Alan Faneca and his ... - 11 p.m. at the Jerome,Bettis Grille 36 on the ... the evening off with an autograph session from 7-8,p.m. Throughout ... of sports,memorabilia will take place. Local sportscaster Bob Pompeani will ...
... PRINCETON, N.J., Sept. 23 Covance Inc. (NYSE:,CVD) today ... Life Sciences,Conference on September 24 at 3:30 pm ET. ... http://www.covance.com . In order to register and,download any ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine News:Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 2Health News:Longs Drugs Announces Immunization Program for the 2007/2008 Flu Season 3Health News:MedCom USA's Subsidiary Card Activation Technologies, Inc.'s SB2 Registration Declared Effective by SEC 2Health News:Clean Hands are Key to Fighting Cold, Flu Germs 2Health News:Jefferson radiation oncologists use real-time system to plant 'seeds' against cancer 2Health News:Super Bowl Champion, Pro Bowler and Pittsburgh Steeler Alan Faneca to Host Sixth Annual 'Bid for Hope' Auction 2
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size. For use in performing free-hand uniform donor buttons....
Each handle is designed to fit a specific trephine size....
Each handle is designed to fit a specific trephine size....
Medicine Products: